Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges

30 Aug 2018

Abstract excerpt

Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally poor prognosis. The emergence of molecular biomarkers has had a significant impact on histological typing and diagnosis, as well as predicting patient survival and response to treatment. The methylation status of the O6-methylguanine-DNA methyl-transferase (MGMT) gene promoter is one such molecular biomarker. Despite the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30189035
DOI: 10.1093/neuonc/noy132

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challengesPMID 30189035Read ↗

MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme.Semantic proximity Read ↗

Personalized treatment strategies in glioblastoma: MGMT promoter methylation statusSemantic proximity Read ↗

Predictive and Prognostic Significance of Molecular Biomarkers in GlioblastomaSemantic proximity Read ↗

Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patientsSemantic proximity Read ↗

Assessing <i>MGMT</i> methylation status and its current impact on treatment in glioblastomaSemantic proximity Read ↗

The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations.Semantic proximity Read ↗

Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort studySemantic proximity Read ↗

The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.Semantic proximity Read ↗

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questionsSemantic proximity Read ↗

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?Semantic proximity Read ↗

Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in GlioblastomaSemantic proximity Read ↗

MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.